Compare ACLS & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACLS | MMED |
|---|---|---|
| Founded | 1995 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.1B |
| IPO Year | 2000 | 2026 |
| Metric | ACLS | MMED |
|---|---|---|
| Price | $150.68 | $11.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $101.50 | $22.56 |
| AVG Volume (30 Days) | ★ 626.2K | 577.4K |
| Earning Date | 05-07-2026 | 06-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $839,048,000.00 | N/A |
| Revenue This Year | $1.93 | $15.99 |
| Revenue Next Year | $7.91 | $10.00 |
| P/E Ratio | $515.90 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $64.17 | $10.65 |
| 52 Week High | $171.61 | $17.86 |
| Indicator | ACLS | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 53.36 | 47.03 |
| Support Level | $78.24 | $10.65 |
| Resistance Level | $171.61 | $12.19 |
| Average True Range (ATR) | 7.81 | 0.74 |
| MACD | -2.01 | 0.14 |
| Stochastic Oscillator | 43.25 | 69.48 |
Axcelis Technologies Inc designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips. In addition to equipment, the company provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. Geographically, the group has a business presence in North America, Asia Pacific, and Europe, of which key revenue is derived from the Asia Pacific.
Minimed Group Inc is a medical technology firm that develops, manufactures, and markets products and solutions for diabetes management. It offers automated insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens as its main products. The company sells these through direct-to-consumer channels and healthcare providers of various countries. The company's revenues are principally derived from the sale of reusable and single-use products which together comprise AID systems and smart multiple daily injection (MDI) systems for diabetes management to individuals, distributors, healthcare providers, and other institutions globally.